Cancer Care Centers of South Texas HOAST CCC of So. TX- San Antonio
Welcome,         Profile    Billing    Logout  
 1 Trial 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wilks, Sharon
NCT06257758: A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Recruiting
1/2
165
US
VIO-01
Valerio Therapeutics
Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
01/26
12/28
BBI-20233042, NCT06052852: Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Recruiting
1/2
147
US
BDC-3042, Cemiplimab, Libtayo, Immune checkpoint inhibitor
Bolt Biotherapeutics, Inc., Regeneron Pharmaceuticals
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma
03/26
03/28
NCT05511844: Study of ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors

Active, not recruiting
1
87
US
ORM-5029
Orum Therapeutics USA, Inc.
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
04/25
10/25
Aponte, Emmalind
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
06/25
12/25
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
NCT05748834: Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Recruiting
2
36
US
Tucatinib, Tukysa, Doxil, doxorubicin hydrochloride liposome injection
SCRI Development Innovations, LLC, Seagen Inc.
Breast Cancer
07/26
07/26
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Active, not recruiting
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
01/26
01/26
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting
N/A
3465
US
Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test
Biotheranostics, Inc.
Breast Cancer
12/28
12/28
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Saenz, Edward
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Active, not recruiting
1
272
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
06/26
08/27
Bock, Alice
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
12/24
12/26
NCT04782687: Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Recruiting
2
100
US
Selinexor, Xpovio, Dexamethasone Oral, Daratumumab, Darzalex, Lenalidomide, Revlimid
US Oncology Research, Karyopharm Therapeutics Inc
Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
05/26
05/26
Korn, Christine
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
Harroff, Allyson L
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
Martinez, Talia
No trials found
Simas, Carmen
No trials found

Download Options